Insights on the Salicylic Head and Neck Cancer Market to 2027
Cancer is a disease
caused when cells divide abnormally and uncontrollably and spread into
surrounding tissues, which results in formation of a mass called tumor. Head and neck cancer refers to various malignant
tumors that develop in or around the mouth, sinuses, nose, larynx, and throat.
Moreover, head and neck cancer begin in squamous
cells that line moist surfaces such as those inside the throat, nose, and
mouth. Infection with human papillomavirus (HPV), excessive alcohol
consumption, and chewing tobacco increases the risk of head and neck cancer.
Other factors such as hereditary causes, Epstein barr virus infection,
radiation exposure, occupational exposure, oral health, salted or preserved
foods, excessive consumption of paan also increases the risk of head and neck
cancer.
Factors such as rise in
government initiatives, surge in research and development activities, rise in
health care infrastructure, and increase in the patient population are expected
to propel the head and neck cancer market. Worldwide, head and neck cancer is the sixth-most common cancer, with
around 630,000 people diagnosed every year, resulting in more than 350,000
deaths, according to the National Center for Biotechnology Information.
Moreover, tens of millions of individuals are diagnosed with cancer each
year and more than half of the patients eventually die from it. Moreover, cancer ranks
the second most common cause of death in many countries, following cardiovascular diseases.
Around 75% of head and neck
cancers are associated with tobacco use. However, in last ten years, the
survival rate of head and neck cancer has dropped to 50% from 80%, as currently
available treatment options primarily treat the symptoms. Furthermore, the introduction
of antibody drug conjugates, monoclonal antibodies, and targeted molecular
therapy such as gene therapy creates major growth avenues for the market. Increasing
incidence of head and neck cancer is also expected to drive the growth of the
market. For instance, around 3 to 5% of the population worldwide suffers from
head and neck cancer, according to the World Health Organization.
In terms of geography, the
head and neck cancer market is divided into six regions, such as North America,
South America, Asia Pacific, Europe, the Middle East, and Africa. Growing
geriatric population, increasing number of initiatives, and increase in product
approvals are creating favorable environment for the head and neck cancer
market growth. For instance, in June 2019, Merck & Co. received the United
States Food and Drug Administration approval for Pembrolizumab for the
treatment of people with metastatic or recurrent head and neck squamous cell
carcinoma.
Comments
Post a Comment